ClinicalTrials.Veeva

Menu

Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto

Q

Quovadis Associazione

Status

Completed

Conditions

COVID-19
Hypercoagulability

Treatments

Drug: Low Molecular Weight Heparin

Study type

Observational

Funder types

Other

Identifiers

NCT04393805
HETHICO

Details and patient eligibility

About

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

Full description

The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.

Furthermore, the possible association between the observed clinical evolution and the type of antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a large cohort of patients hospitalized in the various participating hospitals in the Veneto region and observed with follow-up. in the short term, gathering information on:

Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs, Interactions with other concomitant drugs, and Risk factors.

The collected data, suitably anonymized, will be used to produce scientific works, the standardization of care paths, and the planning of targeted training events.

Enrollment

744 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • proved SARS-COVID-2 infection

Exclusion criteria

  • none

Trial design

744 participants in 2 patient groups

MED-Cohort
Description:
Patients hospitalized for SARS-COVID-2 infection in a medical ward
Treatment:
Drug: Low Molecular Weight Heparin
ICU-Cohort
Description:
Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
Treatment:
Drug: Low Molecular Weight Heparin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems